J
Jason Fangusaro
Researcher at Children's Memorial Hospital
Publications - 104
Citations - 3968
Jason Fangusaro is an academic researcher from Children's Memorial Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 30, co-authored 79 publications receiving 3224 citations. Previous affiliations of Jason Fangusaro include Northwestern University & Nationwide Children's Hospital.
Papers
More filters
Journal ArticleDOI
Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations
Pawel Buczkowicz,Christine M. Hoeman,Patricia Rakopoulos,Sanja Pajovic,Louis Letourneau,Misko Dzamba,Andrew Morrison,Peter W. Lewis,Eric Bouffet,Ute Bartels,Jennifer Zuccaro,Sameer Agnihotri,Scott Ryall,Mark Barszczyk,Yevgen Chornenkyy,Mathieu Bourgey,Guillaume Bourque,Alexandre Montpetit,Francisco Cordero,Pedro Castelo-Branco,Joshua Mangerel,Uri Tabori,King Ching Ho,Annie Huang,Kathryn R. Taylor,Alan Mackay,Anne Bendel,Javad Nazarian,Jason Fangusaro,Matthias A. Karajannis,David Zagzag,Nicholas K. Foreman,Andrew M. Donson,Julia V Hegert,Amy Smith,Jennifer A. Chan,Lucy Lafay-Cousin,Sandra E. Dunn,Juliette Hukin,Chris Dunham,Katrin Scheinemann,Jean Michaud,Shayna Zelcer,David A. Ramsay,Jason E. Cain,Cameron Brennan,Mark M. Souweidane,Chris Jones,C. David Allis,Michael Brudno,Michael Brudno,Oren J. Becher,Cynthia Hawkins +52 more
TL;DR: This work integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPG.
Journal ArticleDOI
Pediatric central nervous system germ cell tumors: a review.
TL;DR: Central nervous system (CNS) germ cell tumors (GCTs) represent approximately 3% of primary pediatric brain tumors and encompass a wide pathologic spectrum and treatment and prognosis differ greatly between groups.
Journal ArticleDOI
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee,Regina I. Jakacki,Arzu Onar-Thomas,Shengjie Wu,Theodore Nicolaides,Tina Young Poussaint,Jason Fangusaro,Joanna J. Phillips,Arie Perry,David C. Turner,Michael D. Prados,Roger J. Packer,Ibrahim Qaddoumi,Sridharan Gururangan,Ian F. Pollack,Stewart Goldman,Lawrence A. Doyle,Clinton F. Stewart,James M. Boyett,Larry E. Kun,Maryam Fouladi +20 more
TL;DR: Selumetinib has promising antitumor activity in children with LGG and the recommended phase II dose (RP2D) and the dose-limiting toxicities (DLTs) of the MEK inhibitor selumet inib inChildren with progressive LGG are determined.
Journal ArticleDOI
Survivin splice variants regulate the balance between proliferation and cell death
Hugo Caldas,Yuying Jiang,Michael P Holloway,Jason Fangusaro,Csaba Mahotka,Edward M. Conway,Rachel A. Altura +6 more
TL;DR: It is shown that the diverse functional roles of survivin can be explained, in part, by its heterodimerization with survivin splice variants in tumor cells, which is likely to have a significant impact in the design of biologic agents for clinical therapy.
Journal ArticleDOI
Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors
Jonathon Torchia,Brian Golbourn,Shengrui Feng,Shengrui Feng,King Ching Ho,Patrick Sin-Chan,Alexandre Vasiljevic,Joseph D. Norman,Paul Guilhamon,Livia Garzia,Natalia R. Agamez,Mei Lu,Tiffany Chan,Daniel Picard,Pasqualino De Antonellis,Dong Anh Khuong-Quang,Aline Cristiane Planello,Constanze Zeller,Dalia Barsyte-Lovejoy,Lucie Lafay-Cousin,Louis Letourneau,Mathieu Bourgey,Man Yu,Deena M.A. Gendoo,Misko Dzamba,Mark Barszczyk,Tiago Medina,Alexandra N. Riemenschneider,A. Sorana Morrissy,Young Shin Ra,Vijay Ramaswamy,Marc Remke,Christopher Dunham,Stephen Yip,Ho Keung Ng,Jian Qiang Lu,Vivek Mehta,Steffen Albrecht,José Pimentel,Jennifer A. Chan,Gino R. Somers,Claudia C. Faria,Lúcia Roque,Maryam Fouladi,Lindsey M. Hoffman,Andrew S. Moore,Yin Wang,Seung Ah Choi,Jordan R. Hansford,Daniel Catchpoole,Diane K. Birks,Nicholas K. Foreman,Doug Strother,Almos Klekner,László Bognár,Miklós Garami,Peter Hauser,Tibor Hortobágyi,Beverly Wilson,Juliette Hukin,Anne Sophie Carret,Timothy E. Van Meter,Eugene Hwang,Amar Gajjar,Shih Hwa Chiou,Hideo Nakamura,Helen Toledano,Iris Fried,Daniel W. Fults,Takafumi Wataya,Chris Fryer,David D. Eisenstat,Katrin Scheinemann,Adam Fleming,Donna L. Johnston,Jean Michaud,Shayna Zelcer,Robert Hammond,Samina Afzal,David A. Ramsay,Nongnuch Sirachainan,Suradej Hongeng,Noppadol Larbcharoensub,Richard Grundy,Rishi Lulla,Jason Fangusaro,Harriet Druker,Ute Bartels,Ronald Grant,David Malkin,C. Jane McGlade,Theodore Nicolaides,Tarik Tihan,Joanna J. Phillips,Jacek Majewski,Alexandre Montpetit,Guillaume Bourque,Gary D. Bader,Alyssa Reddy,G. Yancey Gillespie,Monika Warmuth-Metz,Stefan Rutkowski,Uri Tabori,Mathieu Lupien,Mathieu Lupien,Michael Brudno,Ulrich Schüller,Torsten Pietsch,Alexander R. Judkins,Cynthia Hawkins,Eric Bouffet,Seung-Ki Kim,Peter B. Dirks,Michael D. Taylor,Anat Erdreich-Epstein,Cheryl H. Arrowsmith,Daniel D. De Carvalho,Daniel D. De Carvalho,James T. Rutka,Nada Jabado,Annie Huang +120 more
TL;DR: It is discovered that differential methylation of a PDGFRB-associated enhancer confers specific sensitivity of group 2 ATRT cells to dasatinib and nilotinib, and it is suggested that these are promising therapies for this highly lethal ATRT subtype.